• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Biodesix Inc.

    5/15/25 4:30:09 PM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Biodesix, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    09075X108

    (CUSIP Number)


    05/12/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09075X108


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,673,880.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,673,880.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,673,880.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    09075X108


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,673,880.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,673,880.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,673,880.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    09075X108


    1Names of Reporting Persons

    Perceptive Credit Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,673,880.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,673,880.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,673,880.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    09075X108


    1Names of Reporting Persons

    PCOF EQ AIV IV, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,137,320.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,137,320.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,137,320.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    09075X108


    1Names of Reporting Persons

    Perceptive Credit Holdings IV, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,536,560.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,536,560.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,536,560.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Biodesix, Inc.
    (b)Address of issuer's principal executive offices:

    919 West Dillon Road, Louisville, CO 80027
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 par value per share (the "Common Stock") of Biodesix, Inc. (the "Issuer") are: Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Credit Advisors LLC ("Perceptive Credit") PCOF EQ AIV IV, LP (the "Opportunity Fund") Perceptive Credit Holdings IV, LP (the "Credit Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. Perceptive Credit is a Delaware limited liability company. The Opportunity Fund is a Delaware limited partnership. The Credit Fund is a Delaware limited partnership.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    09075X108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 146,563,031 shares of Common Stock outstanding as of May 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2025 and give effect to the exercise of the Warrants (as defined below). The Credit Fund directly holds (i) 1,036,560 shares of Common Stock and (ii) 5,500,000 warrants to purchase shares of Common Stock (the "Warrants"), consisting of (a) 5,000,000 warrants that are currently exercisable at an exercise price of $1.0648 per share and (b) 500,000 warrants that are currently exercisable at an exercise price of $1.6254 per share. The Opportunity Fund directly holds 1,137,320 shares of Common Stock. The Warrants may not be exercised if the Reporting Persons would beneficially own more than 9.99% of the Issuer's outstanding shares of Common Stock after giving effect to such exercise. Accordingly, the Credit Fund and Opportunity Fund could currently exercise all of their Warrants. Perceptive Credit serves as the investment manager to each of the Credit Fund and Opportunity Fund and as relying advisor under Perceptive Advisors. Perceptive Credit Opportunities GP, LLC serves as the general partner of the Credit Fund. PCOF EQ AIV GP, LLC serves as the general partner of the Opportunity Fund. Mr. Edelman is the managing member of Perceptive Advisors. Each of Perceptive Advisors, Perceptive Credit and Mr. Edelman may be deemed to beneficially own the securities of the Issuer held by the Credit Fund and the Opportunity Fund.
    (b)Percent of class:

    Perceptive Advisors: 5.1% Mr. Edelman: 5.1% Perceptive Credit: 5.1% The Opportunity Fund: 0.8% The Credit Fund: 4.3
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Perceptive Credit: 0 The Opportunity Fund: 0 The Credit Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 7,673,880 Mr. Edelman: 7,673,880 Perceptive Credit: 7,673,880 The Opportunity Fund: 1,137,320 The Credit Fund: 6,536,560

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Perceptive Credit: 0 The Opportunity Fund: 0 The Credit Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 7,673,880 Mr. Edelman: 7,673,880 Perceptive Credit: 7,673,880 The Opportunity Fund: 1,137,320 The Credit Fund: 6,536,560

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:05/15/2025
     
    Perceptive Credit Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
     
    PCOF EQ AIV IV, LP
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
     
    Perceptive Credit Holdings IV, LP
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
    Get the next $BDSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schuler Jack W bought $999,997 worth of shares (142,045 units at $7.04) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/23/25 9:29:04 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $111,425 worth of shares (18,373 units at $6.06) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/19/25 10:31:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $1,500,000 worth of shares (3,488,372 units at $0.43) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/3/25 4:42:40 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

    Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings. At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago

    12/3/25 8:22:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Third Quarter 2025 Results and Highlights

    Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. "We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year," said Scott Hutton, Chief Exe

    11/3/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

    LOUISVILLE, Colo., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces its Corporate and Scientific presentations, and exhibitor presence at the 2025 AMP Annual Meeting, November 12-15, in Boston, MA. BIODESIX WORKSHOP: On November 12, at 4:00 ET, Dr. Gary Pestano, Chief Development Officer, will lead a Biodesix Corporate Workshop focused on the company's R&D Roadmap, including both near- and longer-term novel diagnostic services and solutions. The panel will include updates from key partners of Biodesix Development Services: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific. WORKSHOP

    10/30/25 6:17:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Vazquez Chris sold $99 worth of shares (13 units at $7.62) and converted options into 31 shares, increasing direct ownership by 2% to 936 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    11/13/25 4:54:19 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Development Officer Pestano Gary Anthony converted options into 69 shares and sold $175 worth of shares (23 units at $7.62), increasing direct ownership by 0.58% to 7,939 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    11/13/25 4:54:07 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Commercial Officer O'Kane Kieran converted options into 75 shares and sold $190 worth of shares (25 units at $7.62), increasing direct ownership by 0.68% to 7,362 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    11/13/25 4:53:56 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    SEC Filings

    View All

    SEC Form 10-Q filed by Biodesix Inc.

    10-Q - BIODESIX INC (0001439725) (Filer)

    11/3/25 4:05:56 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIODESIX INC (0001439725) (Filer)

    11/3/25 4:02:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Biodesix Inc.

    8-K - BIODESIX INC (0001439725) (Filer)

    10/1/25 4:05:22 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix downgraded by William Blair

    William Blair downgraded Biodesix from Outperform to Mkt Perform

    5/14/25 8:54:25 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Biodesix

    Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

    9/16/24 8:45:16 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Biodesix with a new price target

    Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

    7/26/24 7:48:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

    12/16/22 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

    12/8/21 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix Announces Third Quarter 2025 Results and Highlights

    Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. "We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year," said Scott Hutton, Chief Exe

    11/3/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

    LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2025 after the close of trading on Monday, November 3. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours aft

    10/20/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces One-for-Twenty Reverse Stock Split

    LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX) ("Biodesix" or the "Company"), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company's common stock will continue to trade under Biodesix's existing trading symbol, BDSX, on the Nasdaq Global Market ("Nasdaq") on a split-adjusted basis when the market opens on Monday, September 15, 2025, with the new CUSIP number 09075X207. The Reverse Stock Split was approved by Biodesix's stockholders at the a

    9/11/25 8:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

    SC 13G/A - BIODESIX INC (0001439725) (Subject)

    11/13/24 7:30:22 AM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Biodesix Inc.

    SC 13G - BIODESIX INC (0001439725) (Subject)

    6/24/24 12:16:38 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

    SC 13D/A - BIODESIX INC (0001439725) (Subject)

    5/23/24 7:10:37 PM ET
    $BDSX
    Medical Specialities
    Health Care